<html>
<head>
    <meta name="GENERATOR" content="Microsoft Visual Studio 6.0">
    <title>Biological Use Authorization</title>
    <!-- <link rel="stylesheet" type="text/css" href="/appAsp/Include/ORA1.css"> -->
    <!-- <link rel="stylesheet" type="text/css" href="/appAsp/Include/Ora_BlueTables.css"> -->
    <link rel="stylesheet" type="text/css" href="/OrPortal/Forms/Compliance/IBC/IBC.css">
    <!-- Get Database Subroutines -->
    
    <!-- End Get Database Subroutines -->
    <!-- #XXXinclude virtual = "/appAsp/Include/StringUtilities.asp" -->
    
    <style>
.OriginalValuesBorder {
    border:3px solid orange;margin-top:5px;
}
.OriginalValuesTitle {
    color:orange;
    font-weight:bold;
}
.highlight {
    background-color:lightyellow; 
    border:1px solid orange;
    padding:2px;
}
.SemiHighlight {
    color:orange;
}
.warning {
    background-color:#FFE4C4; 
    border:1px solid orange;
    padding:2px;
}

th, .thBlue	{
	text-align:left;
	vertical-align:top;
	font-size:8pt;
	font-weight:bold;
	font-family:verdana;
}
td, .tdBlue	{
	text-align:left;
	vertical-align:top;
	font-size:8pt;
	font-family:verdana;
}

.THLine1 {
	color:navy;
	background:#F5F5F5;
	font-size:8pt;
	font-weight:bold;
}
.TDLine1 {
	color:navy;
	background:#F5F5F5;
	font-size:8pt;
}

.THLine2 {
	color:navy;
	background:white;
	font-size:8pt;
	font-weight:bold;
}
.TDLine2 {
	color:navy;
	background:white
	font-size:8pt;
}


.GlobalTd {
	background:white;
	color:navy;
	font-size:9pt;
}
.hdg1 {
	background:white;
	color:navy;
	font-size:12pt;
	font-weight:bold;
}
.xxxhdg2 {
	background:white;
	color:brown;
	font-size:11pt;
	font-weight:bold;
}
.hdg2 {
	background:navy;
	color:white;
	font-size:11pt;
	font-weight:bold;
	margin:1px;
	border-width:1px;
	border-color:white;
	padding:2px;
}
.hdg3 {
	background:white;
	color:navy;
	font-size:12pt;
	font-weight:bold;
}


</style>
    <script>window.status='ORA Production Database';</script>
</head>
<body>
    <form action method="POST" id="form1" name="form1">
        <!-- Outer Table -->
        <table width="650" cellpadding="2" cellspacting="0" border="1">
            <tr>
                <td class="GlobalTd">
                    <script>window.status='ORA Production Database';</script><table width="100%" cellpadding="0" cellspacing="0" border="0px">
<tr>
<td>Protocol#: B-20170014<br><br><div class="hdg1" align="center">University of California, Riverside<br>Institutional Biosafety Committee (IBC)<br>Application for Biological Use Authorization Registration</div>
<br><div class="hdg2">A. INVESTIGATOR DATA</div>
<table border="0" cellpadding="1" cellspacing="1" width="100%">
<tr>   <th class="THBlue">Principal Investigator</th>   <td class="TDBlue">Yinsheng  Wang</td>
<td rowspan="10">&#160;&#160;&#160;&#160;&#160;</td>   <th class="THBlue">Email</th>   <td class="TDBlue">yinsheng.wang@ucr.edu</td>
</tr>
<tr>   <th class="THBlue">Department</th>   <td class="TDBlue">Chemistry</td>   <th class="THBlue">Phone</th>   <td class="TDBlue">(951)827-2700</td>
</tr>
<tr>   <th class="THBlue">Project Start/End Date</th>   <td class="TDBlue">7/1/2006-6/30/2017</td>   <th class="THBlue">Fax</th>   <td class="TDBlue">(951)827-4713</td>
</tr>
<tr>   <th class="THBlue" colspan="5">
<br>Project Title:</th>
</tr>
<tr>   <td class="TDBlue" colspan="5">Posttranslational regulations of proteins and CRISPR-Cas9 for genome engineering</td>
</tr>
<tr>   <th class="THBlue" colspan="5">
<br>Related Funding Agency(ies) (add as many as apply, even if use of rDNA is identical for each project):</th>
</tr>
<tr>   <td class="TDBlue" colspan="5">The National Institute of Health and California Tobacco-Related Disease Research Program</td>
</tr>
<tr><td colspan="5">&#160;</td></tr>
<tr>   <th class="THBlue" colspan="2">Additional Contact person and phone # (if not or in addition to the PI):</th>   <td class="TDBlue" colspan="2">Lin Li, 951-827-2593</td>
</tr>
</table>
<br><br><div class="hdg2">B. RESEARCH LOCATIONS</div>
<table border="1" width="100%" cellpadding="1" cellspacing="0">
<tr>   <th class="THBlue" width="15%">Building &#160;&#160;&#160;</th>   <th class="THBlue" width="15%">Room #  &#160;&#160;&#160;</th>   <th class="THBlue" width="55%">List any containment facilities or equipment (biosafety cabinets, etc.) and their last certification dates. &#160;&#160;&#160;</th>   <th class="THBlue" width="15%">Certification<br>Date</th>
</tr>
<tr>   <td class="TDBlue">Chemical Sciences&#160;&#160;&#160;</td>   <td class="TDBlue">347&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">Chemical Sciences&#160;&#160;&#160;</td>   <td class="TDBlue">341&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">Chemical Sciences&#160;&#160;&#160;</td>   <td class="TDBlue">339&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">Chemical Sciences&#160;&#160;&#160;</td>   <td class="TDBlue">349&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">Chemical Sciences&#160;&#160;&#160;</td>   <td class="TDBlue">345&#160;&#160;&#160;</td>   <td class="TDBlue">Biosafety Cabinet&#160;&#160;&#160;</td>   <td class="TDBlue">9/19/2016&#160;&#160;&#160;</td>
</tr>
</table>
<br><br><div class="hdg2">C. PRIOR APPROVAL STATUS</div>
<table border="0" cellpadding="7" cellspacing="0">
<tr>   <th width="50%" class="THBlue">Application Type</th>   <td width="50%" class="TDBlue">Renewal</td>
</tr>
<tr>   <th class="THBlue">If &#8220;Yes&#8221;, please list the number of the approved protocol</th>   <td class="TDBlue">B-2009</td>
</tr>
<tr>   <th class="THBlue">Does this project involve human or animal subjects, or a positive disclosure of a conflict of interest (income, loans, or management role in funding source, etc.)?</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">If &#8220;Yes&#8221;, has this project been reviewed by any other UCR review boards?  If so, indicate the relevant protocol numbers and approval dates:</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">IRB (human subjects)</th>   <td class="TDBlue">B-2009</td>
</tr>
<tr>   <th class="THBlue">IACUC (animal subjects)</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Conflict of interest (provide approval date)</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Does this project involve strains of plant or animal pathogens not originating in California?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;Yes&#8221;, CDFA and APHIS permits may be required.  List the relevant permit numbers and dates covered:</th>
</tr>
<tr>   <th class="THBlue">CDFA</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">APHIS</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Do experiments involve releasing organisms containing rDNA into the environment?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;Yes&#8221;, has an application for this release been filed with a state or federal regulatory agency?	Agency and date filed:</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Will you be using  a "Select Agent" (<a href="http://www.cdc.gov/od/ohs/lrsat.htm">www.cdc.gov/od/ohs/lrsat.htm</a>)</th>   <td class="TDBlue">False</td>
</tr>
</table>
<br><br><div class="hdg2">DESCRIPTION OF PROJECT</div>
<table border="0" cellpadding="7" cellspacing="0">
<tr>   <th class="THBlue">Provide a brief, non-technical description and purpose of the project.</th>
</tr>
<tr>   <td class="TDBlue">Project 1:  The purpose is to isolate the high-mobility group proteins and other proteins, from human breast cancer tissues, control normal breast tissues, and cultured human cells.  The isolated proteins will be characterized by mass spectrometry, with the goal to determine whether the post-translational modifications of these proteins can serve as molecular biomarkers for cancer diagnosis.  We will also examine the post-translational modifications of DNMT1, eIF5A, and chromosomal proteins including histones and HMG proteins.  Plasmids for the expression of these proteins will be constructed to allow for the ectoptic expression of these and related proteins.  Moreover, site-directed mutagenesis will be used to construct vectors allowing for the expression of the mutated versions of these proteins.

Project 2-4:  The goals of these projects are to understand how DNA adducts perturb the efficiency and fidelity of DNA replication in cells.  To this end, we need to construct plasmid DNA containing a site-specifically introduced DNA adduct and allow these plasmid DNA to replication in cultured human cells (which include Hela, MCF-7, 293T, Jurkat-T, HCT-116, XPV) and mouse embryonic cells that are proficient in translesion synthesis or deficient in translesion synthesis DNA polymerases including pol eta, pol iota, pol kappa, Rev1, and Rev3.  For studies in human cells, siRNA techniques will also be used to knock down the expression of the above-described translesion synthesis DNA polymerases.

In the last project, we will also use CRISPR-Cas9 to knock out those genes that are involved in translesion DNA synthesis, DNA repair and epigenetic modifications in cultured human cells.  We will also employ the CRISPR-Cas9 genome editing method to introduce FLAG and other affinity tags to endogenous loci of the aforementioned genes, which will allow us to pull-down the proteins encoded by those genes for the subsequent mass spectrometric studies.
  </td>
</tr>
<tr>   <th class="THBlue">What are the specific objectives of the work with biohazardous materials?</th>
</tr>
<tr>   <td class="TDBlue">The purpose of this project is to to determine whether the post-translational modifications of these proteins can serve as molecular biomarkers for cancer diagnosis.  Another objective is to explore the molecular mechanisms of translesion synthesis, DNA repair, and epigenetic modifications.</td>
</tr>
</table>
<br><br><div class="hdg2">Potentially Biohazadous Materials</div>Please indicate yes or no if the following biohazardous materials are used currently within your laboratory or are proposed with the next year.  Please check all that apply.<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>   <th colspan="2"><span class="hdg3">Human or Animal Infectious Agents</span></th>
</tr>
<tr>   <th class="THLine1">Viruses</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Bacteria</th>   <td class="TDLine2">True</td>
</tr>
<tr>   <th class="THLine1">Fungi</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Prions</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Other</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th colspan="2">
<br><span class="hdg3">Plant Infectious Agents</span>
</th>
</tr>
<tr>   <th class="THLine1">Viruses</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Bacteria</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Fungi</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Other</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th colspan="2">
<br><span class="hdg3">Recombinant DNA</span>
</th>
</tr>
<tr>   <th class="THLine1">Recombinant DNA in any form.</th>   <td class="TDLine1">True</td>
</tr>
<tr>   <th class="THLine2">Intentional release to the environment</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Other</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th colspan="2">
<br><span class="hdg3">Transgenic Plants</span>
</th>
</tr>
<tr>   <th class="THLine1">Plants</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Liverworts</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Mosses</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Algae</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Other</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th colspan="2">
<br><span class="hdg3">Animals</span>
</th>
</tr>
<tr>   <th class="THLine1">Animals that are potential reservoirs of zoonotic diseases<br>(primates, wild animals, etc.)</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Infectious or hazardous agents in animals</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Human or primate cells in animals</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Transgenic animals</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Other</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th colspan="2">
<br><span class="hdg3">Invertebrates</span>
</th>
</tr>
<tr>   <th class="THLine1">Exotic Arthropods</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Nematodes</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Intentional release to the environment</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th class="THLine2">Transgenic Insects</th>   <td class="TDLine2">False</td>
</tr>
<tr>   <th class="THLine1">Other</th>   <td class="TDLine1">False</td>
</tr>
<tr>   <th colspan="2">
<br><span class="hdg3">Human Stem Cells</span>
</th>
</tr>
<tr>   <th class="THLine1">Human Stem Cells</th>   <td class="TDLine1">False</td>
</tr>
</table>
<br><div class="hdg2">Human or Animal Infectious Agents</div>
<table width="100%" border="1" cellpadding="1" cellspacing="0">
<tr>   <th class="THBlue">List of Agents &#160;&#160;&#160;</th>   <th class="THBlue">Host of Range of Agent &#160;&#160;&#160;</th>
</tr>
<tr>   <td class="TDBlue">Human cell lines and tissues&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">E. coli, BL21-DE3&#160;&#160;&#160;</td>   <td class="TDBlue">&#160;&#160;&#160;</td>
</tr>
</table>
<table border="0" cellpadding="7" cellspacing="0">
<tr>   <th width="50%" class="THBlue">Are you using the wild-type of the agent?</th>   <td width="50%" class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">Are you using genetically modified infectious agents (rDNA, mutagenesis, etc.)?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes,&#8221; please describe the agent and any potential safety issues.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Do the experiments have the potential to increase the host range of the agent?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">Is the vector replication competent?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">Are you using fusion proteins or cell entry domains?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes,&#8221; please describe any safety precautions you would recommend.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Are you using human or primate blood, blood products, cells, cell lines or tissues</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">If &#147;yes,&#148; please describe the blood, blood products, cells, cell lines or tissue and detail how the sample will be worked with during experimentation. Please include vendor information such as the ATCC number if available.</th>   <td class="TDBlue">Human cell lines (HEK293T, HeLa, WM-115, WM-266-4, U2OS, HCT-116, GM00637, GM04429, MCF7).

Human breast cancer and lung cancer as well as control normal tissues will be used.  The tissues will be homogenized and cells will be lysed. The resulting lysis mixture will be extracted with acid to obtain the desired proteins.  The tissues will be purchased from National Disease Research Exchange, Inc.  
Human acute lymphoblastic leukemia cells will also be obtained from ALLCells, Inc., and the DNA and RNA will be extracted from these cells for gene expression and cytosine methylation analyses.</td>
</tr>
</table>
<br><div class="hdg2">Recombinant DNA</div>
<table width="100%" border="1" cellpadding="1" cellspacing="0">
<tr>   <th class="THBlue">General features of the DNA &#160;&#160;&#160;</th>   <th class="THBlue">Species from which DNA originated &#160;&#160;&#160;</th>   <th class="THBlue">Species to receive DNA, type of vector, and transformation method &#160;&#160;&#160;</th>
</tr>
<tr>   <td class="TDBlue">Plasmid DNA encodes green fluorescent protein (from jelly fish), human DNA cytosine methyltransferase I (DNMT1), high mobility group proteins, human translation initiation factor eIF5A, histone protei&#160;&#160;&#160;</td>   <td class="TDBlue">Cultured human cells and mouse embryonic fibroblast cells&#160;&#160;&#160;</td>   <td class="TDBlue">Cultured human cells and mouse embryonic fibroblast cells. The transfection will be done by using Lipofectamine 2000.   &#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">The DNA encode SV40 Large T antigen, human histone deacetylase 4, human RCC1, and related proteins will be handled.  The first one is from virus.  HDAC4 and RCC1 might be involved with cell cycle prog&#160;&#160;&#160;</td>   <td class="TDBlue">SV40 virus (SV40 large T antigen) and human.&#160;&#160;&#160;</td>   <td class="TDBlue">cultured human celles will receive the plasmid DNA and Lipofectamine 2000 will be used as transfection reagents.&#160;&#160;&#160;</td>
</tr>
<tr>   <td class="TDBlue">DNA repair proteins, translesion synthesis DNA polymerases, histone modifying enzymes, and DNA modifying enzymes.  Some constructs encode fluorescent proteins or anti-biotic resistance genes. &#160;&#160;&#160;</td>   <td class="TDBlue">Humans, mouse and jellyfish&#160;&#160;&#160;</td>   <td class="TDBlue">Human cell lines and E. coli&#160;&#160;&#160;</td>
</tr>
</table>
<table border="0" cellpadding="7" cellspacing="0">
<tr>   <th width="50%" class="THBlue">Will cultures of any recombinant organisms listed above exceed a volume of 10 liters?  </th>   <td width="50%" class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If so, where will the cultures be grown?</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Does your experiment involve the transfer of a drug resistance trait to any microorganism, plant, or insect that does not acquire that trait naturally?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, describe any potential environmental or health hazards of the experiments, including whether acquiring such a trait would compromise the use of the drug in medicine or agriculture.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Are you expressing genes encoding toxins with LD 50 less that 10 ng/kg of body weight?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, describe the toxic product and safety precautions.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Are you using hosts or vectors of rDNA (excluding E. coli K-12) that are viable pathogens of animals, plants, or microbes?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, describe any potential environmental or health hazards, containment precautions, and disposal protocols.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Are you using recombinant DNA molecules containing the partial genome of any eukaryotic (plant or animal) virus?</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, describe the molecules, including genetic maps and the fraction of virus genome present, and safety precautions.</th>   <td class="TDBlue">SV40 large T antigen gene will be involved. The manipulation of the plasmid and transformation will be performed in biosafety cabinet.</td>
</tr>
<tr>   <th class="THBlue">Are your experiments likely to enhance the pathogenicity or extend the host range of a viral vector (e.g., introduction of novel control elements or a oncogene)?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, describe the hazards and safety precautions.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Will you be using genes involved in cell cycle control in animals (oncogene, tumor suppressor, cytokine, etc.)?</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, describe the potential hazards.</th>   <td class="TDBlue">We will always handle the transformation of these cells in biosafety cabinet.  All the relevant cell culture manipulation (subculture, medium addition, etc.) will also be performed in biosafety cabinet.</td>
</tr>
<tr>   <th class="THBlue">Medical surveillance requirements or practices that you would recommend (antibody titering, etc.)?</th>   <td class="TDBlue">False</td>
</tr>
<tr>   <th class="THBlue">If &#8220;yes&#8221;, list your recommendations in section 5.</th>   <td class="TDBlue"></td>
</tr>
</table>
<br><br><div class="hdg2">Define Controls</div>
<table border="0" cellpadding="7" cellspacing="0">
<tr>   <th class="THBlue" width="50%">Do you need special equipment, engineering safeguards or personal protective equipment to maintain containment of your experiments (hoods, negative pressure rooms, gloves, etc.) </th>   <td class="TDBlue" width="50%">False</td>
</tr>
<tr>   <th class="THBlue"> If &#8220;yes&#8221;, list your recommendations.</th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Medical surveillance requirements or practices that you would recommend (antibody titering, etc.)? </th>   <td class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Suggested level of biological containment.</th>   <td class="TDBlue">BSL2</td>
</tr>
</table>
<br><div class="hdg2">Acknowledgement of Responsibilities</div>
<div class="tdBlue">For each of the elements below, please indicate if you will be following the UCR standard operating procedures and/or policies. If you indicate &#8220;yes&#8221; then you agree to and must follow the standard procedures and/or policies. If you answer &#8220;no,&#8221; please enter a brief description (in the space provided below the question) of the procedure you will follow and include a justification for deviating from the standard procedure and/or policy.</div>
<table border="0" width="100%" cellpadding="7" cellspacing="0">
<tr>   <th class="THBlue">Decontamination of biohazardous spills: I will used a 0.5 % sodium hypochlorite  (1:10 dilution of household bleach) to decontaminate equipment and work surfaces.  In locations where bleach would cause corrosion, I will decontaminate with an iodophor (e.g., Wescodyne).</th>   <td class="TDBlue" nowrap>True</td>
</tr>
<tr>   <td colspan="2" class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">Storage: Biohazardous material will be clearly labeled with the universal biohazard symbol.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <td colspan="2" class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">If I am using human or non-human primate blood or blood products, unfixed tissue, bodily fluids or organ or cell cultures of human origin, I will follow the exposure control plan for bloodborne pathogens.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <td colspan="2" class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">All injuries and accidental inoculation, ingestion or inhalation of biohazardous material will be reported immediately to the lab director or supervisor and EH&amp;S (827-2648).  Dial 911 immediately for any medical emergency.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <td colspan="2" class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">All shipments of biological materials will follow university policy and all applicable federal and international regulations whenever shipped domestically or internationally.  Proper importation or exportation permits and licenses will be obtained before shipping or reviving biological materials to or from any international location.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <td colspan="2" class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">If I am generating medical and/or biohazardous waste, I will abide by the UC Riverside Medical and/or Biological waste plans.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <td colspan="2" class="TDBlue"></td>
</tr>
<tr>   <th class="THBlue">I understand that UC Riverside may be required by law to release a copy of this application to the public.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">I understand that failure to comply with the applicable regulations governing the use of biohazardous materials described above may result in suspension of the authorization and might jeopardize any funding supporting the activities described herein.</th>   <td class="TDBlue">True</td>
</tr>
<tr>   <th class="THBlue">I attest that I will conduct the study identified above in the manner described.  If I decide to make any changes in the procedure or if any problems occur which involve risk or the possibility of risk to others, I will immediately report such occurances or contemplated changes to the UCR Institutional Biosafety Committee, Research and Economic Development, 200 University Office Building, ext 2-4809; IBC@ucr.edu.</th>   <td class="TDBlue">True</td>
</tr>
</table>
<br><table border="0" width="100%" cellpadding="0" cellspacing="0">
<tr>
<td>______________________________</td>
<td>___________</td>
<td rowspan="2">&#160;&#160;&#160;&#160;</td>
<td>______________________________</td>
<td>___________</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Date</td>
<td>Co-Investigator</td>
<td>Date</td>
</tr>
</table>
<br><em>Electronically signed and submitted to ORA on 4/6/2017 9:47:06 PM by <b>Yinsheng Wang</b></em><hr>IBC CERTIFICATION<div class="tdBlue">I certify that the Institutional Biosafety Committee has reviewed the proposed project.  In compliance with NIH guidelines and other specific NIH instructions, the project is (check one)<br><img src="/appAsp/images/CheckedBox.gif"> Approved as is.<br><img src="/appAsp/images/CheckBox.gif"> Approved with the following conditions:<br><br><br>
</div>
<table border="0" width="100%" cellpadding="0" cellspacing="0">
<tr>
<td>Level:	<img src="/appAsp/images/CheckBox.gif">BL1 &#160;&#160;<img src="/appAsp/images/CheckedBox.gif">BL2 &#160;&#160;<img src="/appAsp/images/CheckBox.gif">BL3 &#160;&#160;<img src="/appAsp/images/CheckBox.gif">BL4 &#160;&#160;</td>
<td>
<em>Electronically Signed by<br><u><b>Djurdjica Coss</b></u></em> __________________________5/31/2017</td>
</tr>
<tr>
<td>&#160;</td>
<td>Chair-Institutional Biosafety Committee &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Date</td>
</tr>
</table>
                    <!-- End Outer Table -->
                </td>
            </tr>
        </table>
    
</td>
</tr>
</table>
</form>
</body>
</html>
